Rodman & Renshaw Initiates Coverage On Quince Therapeutics with Buy Rating, Announces Price Target of $70

Rodman & Renshaw analyst Seema Sheoran has initiated coverage on Quince Therapeutics (NASDAQ: QNCX) with a Buy rating. The firm has set a price target of $70 for the stock.